INDUSTRY × Adenocarcinoma × Gastrointestinal × Clear all
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT07124000 2026-03-31

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 8 FDA
NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Active not recruiting
48 enrolled